SDF-1 binding nucleic acids and the use thereof
The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
1. A method for mobilizing a cell that expresses a receptor for SDF-1 comprising exposing said cell to an L-nucleic acid antagonist of SDF-1 or a homolog thereof, each which binds SDF-1, wherein said L-nucleic acid comprises SEQ ID NO:67 and said homolog comprises at least 85% homology to the entire length of SEQ ID NO:67.
2. The method according to claim 1 , wherein said cell is a progenitor cell or a stem cell.
3. The method according to claim 1 , wherein said exposing is in a subject with a disease or a disorder.
4. The method according to claim 3 , wherein said disease is a cancer; a nephropathy; hypertension; a fibrosis; is associated with improper angiogenesis or neovascularization; involves a diseased organ; involves a diseased tissue; an immunodeficiency; or an autoimmune disease.
5. The method according to claim 3 , wherein said disorder is a wound; a burn; a damaged organ, a damaged tissue, associated with a stroke, associated with a heart attack, associated with ischemia, a chemical-induced blood disorder, a bacterial or a viral infection, associated with transplant of an organ or tissue, an inflammatory response or an allergic reaction.
6. The method according to claim 5 , wherein said damaged tissue comprises a vessel, a retina or a choroid.
7. The method according to claim 3 , further comprising chemotherapy and/or radiotherapy.
8. The method according to claim 4 , wherein said autoimmune disease is of the gastrointestinal tract, the skin, the vasculature, the nervous system or the musculo-skeletal system.
9. The method according to claim 4 , wherein said autoimmune disease is selected from the group consisting of Cogan syndrome, autoimmune adrenalitis, Ménière's disease, local inflammations, alopecia greata, primary biliary cirrhosis, Sjörgen's syndrome, scleroderma, CREST syndrome, uveitis, Hashimoto thyroiditis, Grave's disease, hepatitis, glomerulonephritis, anti-phospholipid syndrome, idiopathic pulmonary fibrosis, infertility and peritonitis.
10. The method according to claim 5 , wherein said transplanted organ is liver, kidney, intestine, lung heart, skin or pancreas.
11. The method according to claim 5 , wherein said transplanted tissue is cornea, blood, an islet of Langerhans, a blood vessel or bone marrow.
12. The method according to claim 5 , wherein said allergic reaction comprises a skin or a mucosa.
13. The method according to claim 3 , wherein said exposing mobilizes cells comprising progenitor cells, long-lived plasma cells, B cells, T cells or stem cells into the peripheral circulation of said subject.
14. The method according to claim 3 , further comprising harvesting said cells from said subject.
15. The method according to claim 14 , wherein said harvesting comprises apheresis, leukapheresis, cell sorting and/or flow cytometry.
16. The method according to claim 14 , further comprising growing said harvested cells in vitro.
17. The method according to claim 14 or 16 , further comprising administering said cells to a subject.
18. The method according to claim 13 , wherein said T cells comprise memory T cells.
19. The method according to claim 3 , further comprising administering an agent that inhibits VEGF.
20. The method according to claim 4 , wherein said diseased tissue comprises age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, macular edema or retinal edema.
21. The method according to claim 4 or 5 , wherein said tissue comprises nervous tissue.
22. The method according to claim 4 , wherein said immunodeficiency is WHIM syndrome.